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Abstract
Background. Therapeutic intervention in metastatic medulloblastoma is dependent on elucidating the underlying 
metastatic mechanism. We investigated whether an epithelial–mesenchymal transition (EMT)-like pathway could 
drive medulloblastoma metastasis.
Methods. A 3D Basement Membrane Extract (3D-BME) model was used to investigate medulloblastoma cell mi-
gration. Cell line growth was quantified with AlamarBlue metabolic assays and the morphology assessed by time-
lapse imaging. Gene expression was analyzed by qRT-PCR and protein expression by immunohistochemistry of 
patient tissue microarrays and mouse orthotopic xenografts. Chromatin immunoprecipitation was used to deter-
mine whether the EMT transcription factor TWIST1 bound to the promoter of the multidrug pump ABCB1. TWIST1 
was overexpressed in MED6 cells by lentiviral transduction (MED6-TWIST1). Inhibition of ABCB1 was mediated by 
vardenafil, and TWIST1 expression was reduced by either Harmine or shRNA.
Results. Metastatic cells migrated to form large metabolically active aggregates, whereas non-tumorigenic/non-
metastatic cells formed small aggregates with decreasing metabolic activity. TWIST1 expression was upregulated 
in the 3D-BME model. TWIST1 and ABCB1 were significantly associated with metastasis in patients (P = .041 and 
P = .04, respectively). High nuclear TWIST1 expression was observed in the invasive edge of the MED1 orthotopic 
model, and TWIST1 knockdown in cell lines was associated with reduced cell migration (P < .05). TWIST1 bound 
to the ABCB1 promoter (P  =  .03) and induced cell aggregation in metastatic and TWIST1-overexpressing, non-
metastatic (MED6-TWIST1) cells, which was significantly attenuated by vardenafil (P < .05).
Conclusions. In this study, we identified a TWIST1–ABCB1 signaling axis during medulloblastoma migration, 
which can be therapeutically targeted with the clinically approved ABCB1 inhibitor, vardenafil.
Key Points
•  TWIST1 and ABCB1 are significantly associated with medulloblastoma metastasis.
•  Overexpression of TWIST1 in non-metastatic cells increased cell aggregation.
•  Inhibiting ABCB1 with vardenafil in a 3D-BME model attenuated cell aggregation.
ABCB1 inhibition provides a novel therapeutic target to 
block TWIST1-induced migration in medulloblastoma
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Medulloblastomas are aggressive malignant pediatric brain 
tumors of the cerebellum that have a high propensity to me-
tastasize (one-third of newly diagnosed medulloblastoma 
patients present with metastatic disease).1,2 Patient re-
sponse to current multimodal therapies which combine 
surgery, chemotherapy, and craniospinal radiotherapy is 
extremely poor, while long-term survivors are left with de-
bilitating side effects (eg, neurocognitive deficits) or have 
a high likelihood of developing recurrent tumors. There is 
an urgent need to improve patient outcomes and eliminate 
treatment-related neurotoxicity by identifying therapies that 
can target specific molecular mediators of metastasis.
Molecularly distinct subgroups are associated with a dif-
ferential propensity to metastasize and are paramount in the 
determination of high-risk tumors.3 Leptomeningeal dissemi-
nation is a well-recognized route of metastasis whereby tumor 
cells disseminate to the leptomeninges of the brain and spinal 
cord via the cerebrospinal fluid.4 Emerging evidence has also 
identified a vascular-mediated route of dissemination whereby 
circulating medulloblastoma cells from the primary tumor were 
present in the bloodstream as observed in the invasion–metas-
tasis cascade, a metastatic process characteristic of epithelial 
tumors.5,6 This suggests that pathways of metastasis identi-
fied in epithelial tumors including the Epithelial–Mesenchymal 
Transition (EMT) pathway, a migratory process that initiates the 
invasion–metastasis cascade,7 could also be relevant during 
metastasis of neuroectodermal medulloblastomas.
During EMT, cells reversibly switch from adhesive ep-
ithelial to motile mesenchymal derivatives. In other 
nonepithelial tumors including glioblastoma,8 activation of 
EMT markers promotes mesenchymal change in an EMT-
like process that regulates stemness, invasion, and therapy 
resistance.9 Identification of several EMT-associated 
markers including BMI1,10 FOXG1,11 MMP9,12,13 Rac1/
PAK1,14 and the uPA/uPAR15 complex in medulloblastomas 
also supports activation of this process.
Three-dimensional (3D) culture systems provide a more 
biologically relevant model compared to cells in 2D cul-
ture; signals from an extracellular matrix (ECM) can restore 
tissue-specific gene expression and function since cell–cell 
and cell–matrix interactions are more representative of the 
original tumor microenvironment.16,17 Here we applied a 
3D preclinical tumor model originally described by Sasser 
et  al.,18 where tumor cells are embedded within low-
stiffness, laminin-rich ECM that incorporates key compo-
nents present in the basement membrane of blood vessels 
and at the leptomeninges (sites of medulloblastoma metas-
tasis).19 Using this model, initiation of an EMT-like process 
was investigated across a panel of medulloblastoma cell 
lines derived from both non-metastatic and metastatic 
(taken from the primary tumor or metastases) patient 
tumor tissue and non-tumorigenic cerebellar progenitors.
We found that only metastatic cell lines migrated to form 
viable 3D aggregates and during this process, the early-
stage EMT transcription factor TWIST1 was upregulated. 
Expression of TWIST1 and the ATP-binding cassette sub-
family B member 1 (ABCB1) multidrug pump (a putative 
TWIST1 downstream target) correlated with poor clinical 
outcome. We confirmed by chromatin immunoprecipitation 
(ChIP) analysis that TWIST1 binds to the promoter region 
of ABCB1 and furthermore showed that TWIST1-induced 
cell migration could be blocked by knocking down TWIST1 
and by targeting TWIST1 or ABCB1 with Harmine or the 
FDA-approved phosphodiesterase-5 inhibitor vardenafil, 
respectively. Our work provides evidence that ABCB1 in-
hibition could provide a promising therapeutic strategy to 
target TWIST1-induced metastasis in medulloblastoma.
Materials and Methods
Patient Characteristics
Clinical and histological data for primary tumor pa-
tient samples for the Birmingham cohort are outlined 
in Supplementary Table S1. Clinical details of patients 
included in tissue microarrays (TMAs) obtained from 
the Children’s Brain Tumour Research Centre (CBTRC), 
Nottingham and German Cancer Research Centre, DKFZ 
were previously published by Othman et al.20 and Dubuc 
et al.,21 respectively. These studies, and the experimental 
protocols required, were reviewed and approved by 
the National Research Ethics Service Committee East 
Importance of the Study
Here, we present a 3D culture system that uses 
tumor-derived basement membrane extract 
(BME) to provide a representative in vitro mi-
croenvironment for medulloblastoma growth 
and metastasis studies reducing the reliance 
on in vivo studies. We show that this 3D-BME 
model can be used to accurately distinguish 
between non-tumorigenic/non-metastatic and 
metastatic cell lines based on morphological 
and transcriptional changes. We provide the 
first conclusive evidence that the EMT factor, 
TWIST1 plays a key regulatory role during 
medulloblastoma metastasis, supporting the 
existence of a migratory EMT-like pathway. 
Furthermore, by identifying a direct link be-
tween the transcription factor TWIST1 and 
the multidrug transporter ABCB1, we provide 
novel therapeutic targets which can be ex-
ploited by re-purposing the ABCB1-specific 
inhibitor vardenafil to block medulloblastoma 
cell migration. These findings provide evidence 
for a novel therapeutic strategy that could be 
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Midlands—Nottingham 2 and the Ethics Committee of the 
Burdenko Neurosurgical Institute (Ethical vote number 
563/6–16) and those of the University of Heidelberg, in 
compliance with the Russian Federation and German re-
gulations of Health Insurance Portability. Both studies were 
in accordance with the ethical standards laid down in an 
appropriate version of the 1975 Declaration of Helsinki, 
as revised in 1983. For all patients, informed consent was 
obtained from the patient, or a parent and/or legal guardian 
where the patient was younger than 18 years of age, prior 
to their inclusion in the study.
Cell Culture
FB83 from human fetal brain tissue and MED1 and MED6 
cell lines from patient medulloblastomas were derived at 
the CBTRC as previously described22,23 with approval from 
Local Research Ethics Committee and cultured in tumor 
media Dulbecco’s modified Eagle’s medium (DMEM, GIBCO: 
11885084)  containing 15% (v/v) fetal bovine serum (FBS, 
Hyclone). MED6 cells were stably transduced in-house 
with a TWIST1 expression vector (based on the pLVX-IRES-
tdTomato plasmid construct from Clontech) according to the 
manufacturer’s instruction to generate the MED6-TWIST1 cell 
line which was cultured in tumor media. UW228-3 was pro-
vided by Dr John R. Silber and cultured as recommended.24 
The C17.2 cell line generated from mouse cerebellar progen-
itor cells was provided by Dr Evan Snyder (Harvard Medical 
School, Massachusetts) and cultured as recommended.25,26 
D283Med27 (ATCC) and D458Med28 were provided by Dr Darell 
Bigner, Duke University and maintained in DMEM supple-
mented with 10% FBS. ONS-76 were provided by Dr Annette 
Künkele, Charité Universitätsmedizin Berlin, Germany and 
maintained in RPMI-1640 medium (Sigma-Aldrich: R8758), 
supplemented with 10% FBS. D283Med and ONS-76 cell lines 
were transduced with TWIST1-shRNA GIPZ Lentiviral clone 
(V3LHS_329863; Dharmacon). About 48 h after infection, the 
cells were selected using 1 µg/ml of puromycin and the knock-
down was confirmed by PCR and western blot analysis.
Murine Metastatic Medulloblastoma Model
The murine model was produced using MED1-Fluc cells 
generated by lentiviral transduction of MED1 cells with the 
in-house luciferase expression vector (pLVX-luc) based on the 
Lenti-XTM Lentiviral Expression System (Clontech) according 
to manufacturer’s instructions to allow visualization in vivo. 
Full experimental methods are detailed in Supplementary 
Methods in accordance with the ARRIVE guidelines. MED1-
Fluc cells with the viability of more than 90%, which had 
been maintained in vitro in tumor media and selected with 
puromycin (4 µg/ml) weekly, were injected at 6 × 104 cells in 
5 µl of PBS (12 × 106 cells/ml) intracranially (at 7 mm poste-
rior to bregma, 1 mm right of the midline, 3 mm deep using 
a 26-gauge Hamilton Gastight 1701 syringe needle) into each 
MF-1/CD-1 nude male mouse (obtained from Harlan, UK at 
8–12 weeks of age). Tumor growth was monitored with bi-
oluminescence whole-body imaging of mice, performed 
twice weekly upon d-Luciferin (120  mg/kg by weight) injec-
tion using the IVIS Spectrum (Caliper Life Sciences). Mice 
were monitored daily and euthanized upon showing any 
signs of adverse effects (eg, neurological deficits). All animal 
experiments were performed in accordance with the United 
Kingdom Animals (Scientific Procedures) Act 1986, under the 
UK Home Office project license authority PPL40/3559. Ethical 
approval was granted by the University of Nottingham Animal 
Welfare and Ethical Review Board.
Immunohistochemistry
Sections of patient brain tumor tissue, TMAs, murine 
brain, and spinal column (10% decalcification) containing 
MED1-Fluc xenografts were stained with anti-TWIST1 
(ABD29; Millipore; 1:250–1:500). Nottingham and German 
TMAs were stained with anti-ABCB1 (C219, Calbiochem; 
1:40; Supplementary Table S2). All immunohistochemistry 
experiments were conducted using the Dako Envision 
Detection kit (DAKO REAL EnVision) as previously de-
scribed by Othman et al.20
Immunofluorescence
MED6 and MED6-TWIST1 cells plated in 8-well 
chamber slides (6  × 103 cells/well) were fixed in 4% 
paraformaldehyde (Sigma) for 15 min, permeabilized with 
0.1% v/v Triton-X100 in PBS (PBS-T; Sigma) for 10 min, and 
blocked with 2% v/v normal goat serum (Life Technologies) 
in PBS-T for 1 h. The primary antibody anti-TWIST1 (1:250) 
was added to cells for 1  h, rinsed with PBS, and subse-
quently incubated with Alexa Fluor 488 anti-rabbit (1:400; 
Life Technologies) for 1 h. Cells were then mounted using 
Vectashield with 4′,6-diamidino-2-phenyl-indole (Vector 
Laboratories) and visualized with inverted fluorescence mi-
croscopy (Nikon Eclipse Ti-U).
3D-BME Migration Assay
Cells were resuspended in ice-cold Cultrex basement mem-
brane extract (BME; 3 mg/ml; Trevigen) diluted in RPMI-1640 
supplemented with 1% w/v l-glutamine and plated (100  µl/
well) at appropriate densities (Supplementary Table S3) in low-
adherent, black-walled, clear-bottom, 96-well plates (BrandTech 
781671) pre-warmed to 37°C. Plates were incubated (5% CO2 
at 37°C) for 30  min to facilitate BME polymerization before 
50 µl of drugs (CCT007093 [Axon Med Chem], Vardenafil [LKT 
Laboratories]) diluted in RPMI-1640 supplemented with 1% 
l-glutamine were added for 96  h exposure. The AlamarBlue 
assay (Invitrogen; 10% v/v, 37°C for 1 h) was used to assess met-
abolic activity daily using a fluorescent plate reader (excitation 
560 nm, emission 588 nm, Flex Station II, Molecular Devices).
3D Transwell Migration Assay
D283Med and ONS-76 cells were pretreated with 5  µM 
or 20  µM of Harmine (Abcam) respectively and incu-
bated (5% CO2 at 37°C) for 48  h. Cells were re-treated 
with Harmine in a medium containing 2% FBS and in-
cubated for a further 24  h. Transwell inserts (Greiner; 
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and Laminin (AMS Bio 5  µg/ insert) in a 24-well plate 
(Greiner). 1 × 105 viable cells were plated on the inserts 
with the outer chamber filled with medium containing 
10% FBS and cells were allowed to migrate for 48  h. 
Media were removed from the chambers and migrated 
cells dislodged from the bottom surface of the insert by 
adding 1× cell dissociation solution (R&D Systems; 5% 
CO2 at 37°C for 1  h). The PrestoBlue assay (Invitrogen; 
10% v/v, 37°C for 10 min) was used to assess metabolic 
activity and quantify cell migration using a fluorescent 
plate reader (excitation 544 nm, emission 590 nm).
Phase Microscopy and Image Analysis
3D-time-lapse images were captured daily using a Nikon 
Eclipse Ti inverted microscope. Images acquired for 
quantification consisted of 3 separate fields obtained for 
each well (n  = 3) from 3 independent experiments. XYZ 
coordinates were fixed on the initial day of set up (day 
0)  and used to create composite images (z-stacks). Cell 
growth was analyzed by converting images into black 
and white, thresholding using the Yen algorithm29 and 
quantifying the mean aggregate area per condition using 
the open-source Fiji software (http://fiji.sc/Fiji). Time-lapse 
videos were taken between days 1 and 6, by automatically 
capturing images per well at 70- to 100-min intervals, to 
assess cell aggregation (Cell-IQ CM Technologies Oy).
Quantitative Real-Time Polymerase Chain 
Reaction
RNA isolation of cell lines with high yield under standard con-
ditions was performed using the mirVana miRNA isolation kit 
(Ambion). RNA isolation of cells with low yield cultured in the 
3D-BME model was lysed with TRI-reagent (Sigma-Aldrich; 
1 ml per 5–10 × 106 cells) and chloroform, precipitated with 
isopropanol and 70% ethanol washes and re-suspended 
in nuclease-free water. RNA samples were transcribed 
into cDNA using reverse transcriptase (Superscript III; 
Invitrogen). Gene expression of the resultant cDNA tem-
plate was assessed by quantitative reverse transcription 
PCR (CFX96 real-time PCR machine; BIORAD) and iQ SYBR 
SuperMix (BIORAD). Primer sequences are summarized in 
Supplementary Table S4. The house-keeping gene GAPDH 
was used as a control to normalize the data and the relative 
mRNA expression level was calculated using the ΔCt method.
Chromatin Immunoprecipitation
D283Med cells were crosslinked with 0.75% 
paraformaldehyde for 7  min, lysed, and sonicated to ob-
tain 200–500  bp chromatin fragments. Protein G beads 
(ThermoFisher Scientific) were incubated overnight at 4°C 
with either 5  μg of anti-TWIST1 (TWIST2C1α) antibody 
(Abcam), negative control IgG1 antibody (Cell Signalling 
Technology), or H3KMe4 antibody (Active Motif), before com-
bining with 25  μg of chromatin fragments and incubating 
overnight at 4°C. The antibody–protein–DNA complexes were 
eluted from the beads and crosslinks reversed using 0.3M 
NaCl at 65°C. DNA was purified by phenol–chloroform extrac-
tion and subjected to qRT-PCR using primers (Supplementary 
Table S5) specific to E-box binding sites within the promoter 
regions of ABCB1, GAPDH, and SNAI2. Active promoter re-
gions were confirmed using the H3K4Me3 antibody.
Statistical Analysis
Patient TMA data were analyzed in SPSS version 24 statis-
tical software (IBM). ABCB1 and TWIST1 expression were 
compared against metastatic status (M0/M+) using Pearson’s 
chi-squared test. All remaining statistical differences were cal-
culated using GraphPad Prism version 7.0. Results were pre-
sented as mean ± standard error. Statistical differences for the 
relative aggregation rate between conditions at each time point 
were assessed using unpaired t-tests corrected for multiple 
comparisons using the Sidak–Bonferroni method. ChIP was 
assessed using a Student’s paired t-test. Gene expression com-
parison between groups was assessed using one-way analysis 
of variance with Tukey’s multiple comparisons post-hoc test. 
P values ≤.05 were considered significant.
Results
Metastatic Medulloblastoma Cells Form 
Metabolically Active Aggregates in a 
3D-BME Model
Culturing cells in 3D tumor microenvironment models 
has been shown to better represent cell growth, mor-
phology, and transcriptional profiles of the tumor. In this 
study, we investigated whether previously defined non-
tumorigenic (C17.225 and FB8323), non-metastatic (MED620 
and UW228-324), and metastatic (MED120, D283Med27 and 
D458Med28) cell lines could be distinguished based on 
the aforementioned factors. The AlamarBlue assay and 
time-lapse imaging were used to assess metabolic activity 
(Figure 1A) and morphology (Figure 1B), respectively, of 
each cell line cultured in serum-free 3D-BME. Metastatic 
cell lines (MED1, D458Med, and D283Med) formed meta-
bolically active cell aggregates viable for 6–9 days, while 
non-tumorigenic/non-metastatic cell lines either formed 
cell aggregates viable for only 3  days (FB83, MED6, and 
UW228-3) or remained as single cells (C17.2). Live-cell im-
aging (CELL-IQ) of the metastatic MED1 cell line, which 
formed large metabolically active aggregates, captured 
cell interactions formed during 6  days of culture in the 
3D-BME model. During the early days of culture (days 1–3; 
Supplementary Video S1), cell aggregates increased in size 
by sequestering single cells to the aggregate body. Later 
days of culture (days 3–6; Supplementary Video S2) pro-
moted aggregates to rapidly increase in size by combining, 
corroborating with reported metastatic phenotypes.30
WIP1 Inhibition Blocks Aggregation in the 
3D-BME Model
Overexpression of the EMT-associated marker WIP1 (wild-
type p53-induced protein1) promotes cell migration and 
invasion in metastatic medulloblastoma patients and 2D 
cell migration models.31,32 To validate the 3D-BME model 
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expression of WIP1 increased in metastatic cell lines grown 
in 3D-BME and if the cells’ aggregation phenotype could be 
blocked by inhibiting WIP1. In 2D culture, WIP1 levels were 
highest in D283Med cells. In the 3D-BME model, WIP1 levels 
increased across all cell lines compared to 2D culture, and 
the metastatic cell lines (D283Med and D458Med) showed in-
creased WIP1 levels compared to the M0 cell lines (Figure 2A).
To block cell aggregation in the 3D-BME model, the high 
WIP1-expressing D283Med cell line was treated with a 
WIP1-specific small molecule inhibitor, CCT007093 for 
72 h32 at nontoxic concentrations (Figure 2B). Exposure to 
CCT007093 significantly attenuated D283Med cell aggre-
gation at days 2 and 3 (Figure 2C and D; P ≤ .01) compared 
to vehicle-treated cells, validating the 3D-BME model as 
modeling aspects of medulloblastoma metastasis.
The EMT Transcription Factor TWIST1 Is a 
Marker of Cell Aggregation and a Driver of 
Medulloblastoma Migration
Activation of the EMT migratory program has been as-
sociated with metastasis of several cancers including 
medulloblastoma, leading us to investigate the expression 
of transcription factors (SNAI2 and TWIST1) that are ex-
pected to initiate the EMT program.33 The publicly available 
Pfister34 and Roth35 patient datasets revealed lower SNAI2 
expression in medulloblastoma patient samples compared 
to the normal cerebellum, whereas TWIST1 expression 
was significantly increased in medulloblastoma samples. 
SNAI2 expression was not observed below the detection 
limit in 2D or 3D samples of the C17.2 or MED1 cell lines. 
High expression of TWIST1 was, however, observed in the 
metastatic MED1 cell line and increased significantly in the 
3D-BME culture (Supplementary Figure S1).
TWIST1 gene expression was assessed in 2D and 3D 
samples of a further 3 cell lines (MED6, UW228-3, and 
D283Med; Figure 3A). In the metastatic cell line (D283Med), 
TWIST1 gene expression was upregulated during 3D-BME 
culture. TWIST1 protein expression was also assessed in 
primary tumor samples corresponding to the MED1 and 
MED6 cell lines. High nuclear expression of the TWIST1 
transcription factor was observed only in the MED1 pri-
mary tumor (Figure 3B and C).
TWIST1 protein expression was then assessed in a TMA 
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Figure 1. Cell growth and morphology in the 3D-BME model. Non-tumorigenic (FB83 and C17.2), non-metastatic (MED6 and UW228-3), and met-
astatic (MED1, D458Med, and D283Med) cell lines were cultured in the 3D-BME model. (A) Metabolic activity was assessed with the AlamarBlue 
metabolic assay to determine the arbitrary fluorescent units (AFU; n ≥ 2). One-way ANOVA statistical tests shown were compared with MED1 (de-
noted in black), FB83 (denoted in red), and UW228-3 (denoted in blue) at days 3 and 6 (*P ≤ .05, **P ≤ .001, ***P ≤ .0005, and ****P ≤ .0001). (B) 
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Birmingham hospitals. Of 70, 45 (64%) samples showed 
high expression (>30% nuclear positivity) of  TWIST1. About 
81% of patients with metastatic disease (M+) showed high 
TWIST1 expression while only 54% of patients categorized 
as M0 at the time the primary tumor was resected showed 
high TWIST1 expression. A  chi-squared test and Kaplan–
Meier analysis showed that TWIST1 expression significantly 
correlated with metastasis and worse event-free survival 
(EFS), respectively (P  =  .027 and .046, respectively; Figure 
3D and E). Metastatic disease and molecular subgroup 
were also significantly correlated with EFS and overall sur-
vival (Supplementary Table S6). Follow-up information on 
36 of the 44 patients categorized as M0 revealed that only 
23% of patients who showed low TWIST1 expression de-
veloped metastatic disease, whereas 58% of patients with 
high TWIST1 expression later developed metastatic disease 
(P = .037; Supplementary Figure S2) further highlighting the 
possible importance of TWIST1 expression as a prognostic 
biomarker in medulloblastoma patients.
TWIST1 protein expression was also assessed in xen-
ograft tissue taken from an in vivo orthotopic model of 
MED1 which developed spinal cord metastases (Figure 
3F–H). TWIST1 expression was observed at the invasive 
edge (Figure 3G) but not in the core (Figure 3G and G) of 
the primary xenograft and in the dorsal root ganglia of 
spinal tumors (Figure 3H and H).
Since high TWIST1 expression was associated with 
patient metastatic disease and the invasive edge of 
medulloblastoma xenografts, we investigated the possi-
bility that TWIST1 can increase cell aggregation due to its 
ability to promote cell migration. We therefore engineered 
a TWIST1 over-expressing cell line by lentiviral transduc-
tion of the non-metastatic MED6 and investigated the ef-
fect on cell aggregation. Expression analysis showed high 
levels of  TWIST1 protein and qRT-PCR revealed an ap-
proximately 50-fold increase in TWIST1 gene expression 
in MED6-TWIST1 (ΔCt value ~0.2) compared to the MED6 
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Figure 2. Investigating the metastatic marker WIP1 in the 3D-BME model. (A) Relative gene expression of WIP1 was assessed in 2D and 3D sam-
ples of medulloblastoma cell lines normalized against GAPDH using the 2−ΔCt method (one-way ANOVA analysis with Tukey’s multiple comparisons 
post-hoc test; *P ≤ .05 and ***P ≤ .001; n = 3). (B–D) D283Med were exposed to CCT007093 (0.5 µM and 5 µM), vehicle (0.1% DMSO), or untreated at 
days 0–3 in the 3D-BME model. (B) Metabolic activity was assessed with the AlamarBlue metabolic assay for each condition (n = 3). (C) Time-lapse 
images of vehicle (black arrows denote cell aggregates) and treated D283Med cells at ×10 magnification (scale bars represent 100 µm). (D) The 
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Figure 3. TWIST1 expression and functional analysis. (A) Relative gene expression of TWIST1 was assessed in 2D and 3D samples of 3 
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The level of TWIST1 gene expression observed in MED6-
TWIST1 was comparable with the MED1 cell line. In 3D cul-
ture, MED6-TWIST1 rapidly formed large cell aggregates 
(Figures 3I and 4D), which resembled the metastatic MED1 
cell line (Figure 1B).
To further explore TWIST1’s potential in driving 
medulloblastoma cell migration, we inhibited its ex-
pression in the highly expressing TWIST1 metastatic cell 
lines D283Med (M2) and ONS-76 (Supplementary Figure 
S4A) either genetically using shRNA or chemically using 
Harmine.36 shRNA treatment resulted in a significant re-
duction in TWIST1 gene expression in the D283Med and 
ONS-76 cell lines by 63% and 68%, respectively, and a com-
parable reduction in protein expression (Supplementary 
Figure 4B and C). Treatment with Harmine (D283Med; 5 µM 
and ONS-76; 20 µM) caused a 77% and 70% reduction in 
TWIST1 protein expression, respectively.36 Subsequent 
to either chemical or genetic knockdown of TWIST1, a 
significant reduction in cell migration was observed 
without impacting cell viability (P ≤ .05; Figure 3J and K; 
Supplementary Figure S5).
ABCB1 Inhibition Can Block Cell TWIST1-Driven 
Migration in Metastatic Medulloblastomas
We have previously correlated the expression of ABCB1 
with high-risk medulloblastoma patients. Metastatic status 
is known for 259 of these patients enabling us to investi-
gate a correlation between metastasis and ABCB1 expres-
sion.20 Positive ABCB1 expression was more likely to be 
observed in metastatic tumors (50.5%) compared to non-
metastatic tumors (37.7%; P = .04; Figure 4A).
We have previously shown that the ABCB1 gene is 
expressed in medulloblastoma cell lines,20 and the 
overexpressing MED6-TWIST1 cell line showed a 4-fold 
increase in ABCB1 gene expression relative to parental 
MED6 cell line (Supplementary Figure S3B). We therefore 
set out to determine if TWIST1 could bind to the E-box lo-
cated on the promoter region of ABCB1 using a ChIP assay. 
TWIST1 is significantly bound to the E-box binding site 
in the Exon3 active promoter region of ABCB1 (P  =  .03) 
and GAPDH (P  =  .018) in D283Med cells (Figure 4B and 
C; Supplementary Figure S6). However, TWIST1 did not 
bind to SNAI2, correlating to the previous results whereby 
SNAI2 was not expressed in both 2D and 3D metastatic cell 
lines (Supplementary Figure S1).
We then analyzed whether inhibition of ABCB1 could af-
fect cell aggregation in medulloblastoma cell lines cultured 
in the 3D-BME model. We treated the ABCB1-high MED1 and 
intermediate-expressing D283Med cell lines with the ABCB1-
specific inhibitor, vardenafil, at a clinically relevant, non-
toxic concentration20,37 (10 µM; Supplementary Figure S7A). 
Cell aggregation was significantly attenuated in both MED1 
and D283Med (Supplementary Figure S7B and C) after ex-
posure to vardenafil for 3 (MED1 P ≤ .01, D283Med P ≤ .05) 
and 4 days (MED1 P ≤ .05, D283Med P ≤ .05). This effect ap-
peared to be more marked in the MED1 cell line, which also 
expresses high levels of  TWIST1 (Supplementary Figure 
S1). Furthermore, the increased aggregation observed in the 
TWIST1-overexpressing MED6 cells could be significantly 
blocked by inhibition of ABCB1 function using vardenafil (P 
≤ .05; Figure 4D and E). The rate of cell aggregation was sig-
nificantly increased in MED6-TWIST1 compared to the MED6 
parental cell line day 4 of 3D culture confirming that TWIST1 
expression induces cell aggregation (Figure 4E).
Discussion
Patients with metastatic disease respond poorly to therapy 
and are classified into high-risk categories.38 In this study, 
we investigated mechanisms of medulloblastoma metas-
tasis using a patient-relevant culture system. The 3D-BME 
model incorporates major ECM components including lam-
inin, collagen IV, entactin, heparan sulfate proteoglycans, 
and several growth factors to mimic the patient’s tumor mi-
croenvironment. In the 3D-BME model, non-tumorigenic/
non-metastatic and metastatic cell lines displayed different 
growth patterns. All cell lines with the exception of immor-
talized cerebellar granule progenitor cells (C17.2; which 
remained as single cells) formed cell aggregates that dis-
played 2 out of 4 previously defined phenotypes (benign 
round, mass, grape-like, and invasive stellate). Neural stem 
cells, non-metastatic MED6, and UW228-3 as well as met-
astatic MED1 displayed a “stellate” morphology, a phe-
notype associated with invasiveness.39 Neural stem cells 
and non-metastatic cell lines however formed small cell 
aggregates which failed to sustain their metabolic activity, 
while the metastatic MED1 formed large cell aggregates 
which maintained their metabolic activity by continually 
migrating and combining. The D283Med and D458Med cell 
lines, derived from metastatic sites, displayed a “grape-
like” morphology with generally smaller aggregates 
of MED1 and (C) MED6 patient tumor tissue at ×20 magnification (scale bars represent 50 µm). (D) Nuclear TWIST1 IHC staining of Nottingham 
and Birmingham TMA’s was scored and correlated with metastatic status (M0/M+) in 70 patients (>3 years old; Pearson’s chi-squared exact test; 
P = .027). (E) High TWIST1 expression correlated to adverse EFS in Kaplan–Meier curves of Nottingham and Birmingham TMA’s (Log-rank test; 
P = .046). (F) Bioluminescent images (obtained at 60 s exposure time) of brain and spinal cord tumors at 21 days after implanting MED1-Fluc cells 
into the mouse cerebellum. (G and H) Nuclear TWIST1 IHC staining of horizontal sections of the (G) brain and (H) right dorsal ganglia tumor of the 
spinal cord taken at ×4 and ×20 magnification (scale bars shown represent 50 µm). (I) MED6 and MED6-TWIST1 morphology with time-lapse im-
ages taken at ×10 magnification (scale bars represent 100 µm). (J and K) TWIST1 was inhibited in D283Med and ONS-76 cell lines using (J) shRNA 
or (K) Harmine (D283Med: 5 µM and ONS-76: 20 µM) for 72 h, before plating (1 × 105 cells/insert) onto a Collagen IV and Laminin coated transwell 
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probably due to their weak cell–cell interactions and cell–
matrix adhesions. These are properties that could facilitate 
the transit of disseminating tumor cells to metastatic sites 
as has been observed by others in aggressive breast39 and 
colorectal40 cell lines derived from metastases.
Live-cell imaging of the MED1 cell line showed direc-
tional movement between multiple cell clusters, a process 
known as chemotaxis-driven cell migration.30 The cell ag-
gregation observed in our study has been recapitulated 
by Puliafito et al.30 where metastatic prostate cancer cells 
(PC3) cultured in BME also increased their aggregate 
size in a directional and chemotaxis-driven process. This 
phenotype is relevant during medulloblastoma dissemina-
tion in the patient, where reports provide evidence that se-
cretory cytokines and growth factors could be responsible 
for promoting chemotaxis cell migration at the leptome-
ningeal membrane.4,6
To assess the relevance of our model, we assessed 
the expression of WIP1, a metastatic medulloblastoma 
marker, which promotes migration through cross-
talk with the chemokine CXCR4 and G-protein-
coupled receptor GRK5.31,41 WIP1 was significantly 
upregulated in the metastatic medulloblastoma cell 


























































































































Figure 4. TWIST1 regulates ABCB1. (A) Membranous ABCB1 IHC staining of DKFZ TMA and Nottingham TMA was scored and correlated with 
metastatic status (M0/M+) in a total of 259 patients (Pearson’s chi-squared exact test P = .04). (B) Schematic of the E-box binding site in the Exon 3 
promoter region of ABCB1. (C) ChIP qPCR analysis of the promoter regions in GAPDH, SNAI2, and ABCB1, showing enrichment with TWIST1 
antibody for GAPDH and ABCB1 compared with IgG antibody control. Data are expressed as a percentage of the input (paired Student’s t-test 
*P ≤ .05; n ≥ 3). (D and E) MED6 and MED6-TWIST1 (2.6 × 104 cells/well) cells were treated with vardenafil (10 µM) or vehicle (H20) at days 0–4 in the 
3D-BME model. (D) Time-lapse images were taken at ×10 magnification (scale bars represent 100 µm). (E) The mean aggregate area was quantified 
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MED6 and UW228-3) and early-stage metastatic (M1; 
D458Med) cell lines. Buss et al. and others have dem-
onstrated that CCT007093 inhibits the proliferation of 
WIP1-expressing cells.32,41,42 In 2D culture, WIP1 inhi-
bition with 5  µM CCT007093 caused cell cytotoxicity. 
However, we show in 3D-BME, that 5  µM CCT007093 
did not induce cytotoxicity but attenuated cell aggrega-
tion, hence demonstrating that in a relevant 3D model 
WIP1 inhibition has the expected effect on cell aggrega-
tion, thus validating the 3D-BME model.31
Emerging evidence identifying the existence of 
medulloblastoma circulating tumor cells during hema-
togenous dissemination has recently highlighted alter-
native routes of metastasis that have previously been 
overlooked. To this end, we assessed the role of the 
EMT transcription factor, TWIST1 in medulloblastoma 
cell migration. TWIST1 was exclusively expressed 
in aggregating cell lines in an in vitro model of 
medulloblastoma metastasis and at the migratory 
edge of an in vivo metastatic medulloblastoma model. 
TWIST1 was also associated with both metastasis at 
diagnosis and relapse in medulloblastoma patients. In 
the 3D-BME model, TWIST1 overexpression in MED6 
cells (which previously failed to form metabolically 
active cell aggregates) induced cell aggregates that 
collectively migrated over 5  days. We knocked down 
TWIST1 using shRNA and degraded TWIST1 protein 
chemically using Harmine,36 allowing for further in-
vestigation of the functional importance of TWIST1 in 
medulloblastoma cell migration. Reduced TWIST1 ex-
pression in the D283Med and ONS-76 cell lines sig-
nificantly decreased cell migration in the 3D transwell 
assay following either genetic or chemical knockdown 
of TWIST1. Both Harmine and shRNA knockdown of 
TWIST1 may have distinct off-target effects; however, 
the fact that both approaches inhibit migration con-
firms a specific role for TWIST1. This supports our hy-
pothesis that, in common with several other types of 
cancer,43 TWIST1 is a master regulator of tumor me-
tastasis in medulloblastoma.
TWIST1 has also been implicated in promoting 
chemoresistance and stemness by co-expression with 
ABC transporters.44–46 We have previously demonstrated 
that the multidrug-transporter ABCB1 contributes to 
chemoresistance in ABCB1-expressing medulloblastoma 
cell lines and that high expression is associated with 
high-risk medulloblastoma tumors.20,22 Here, we con-
firmed that ABCB1 is associated with metastasis in pa-
tients, providing further evidence linking ABCB1 with 
invasion.47–49 In support of this, we show that the clini-
cally approved ABCB1 inhibitor vardenafil could be used 
to inhibit cell aggregation in ABCB1-expressing cell lines 
cultured in the 3D-BME models, with a more dramatic ef-
fect observed in MED6-TWIST1.49,50 Using ChIP pulldown 
analyses we also demonstrated that TWIST1 binds to 
the E-box on the promoter region of ABCB1. Further ge-
netic knockdown experiments are required to elucidate 
how  TWIST1 is regulating ABCB1 and whether dual 
TWIST1/ABCB1 inhibition has the potential to prevent 
medulloblastoma metastasis.
In conclusion, we identified a role for TWIST1 during 
medulloblastoma metastasis and demonstrate the po-
tential of therapeutically inhibiting ABCB1 with the FDA-
approved vardenafil to prevent metastasis.
Supplementary Material
Supplementary material is available at Neuro-Oncology 
Advances online.
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